
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Born almost 3 years ago, the set of federal measures for quality care for children in Medicaid and CHIP is being slowly pushed out of infancy; however, states are having difficulties gathering and reporting data, which may keep some of the measures aspirational for some time.






